Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RiMO 301

Next Previous
Drug Profile

RiMO 301

Alternative Names: RiMO-301

Latest Information Update: 26 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RiMO Therapeutics
  • Developer Coordination Pharmaceuticals; RiMO Therapeutics; University of Chicago
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II Head and neck cancer
  • No development reported Prostate cancer

Most Recent Events

  • 16 Jun 2025 Coordination Pharmaceuticals completes a phase I trial in Solid tumour (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (Intratumoural) (NCT03444714)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Late-stage disease, Metastatic disease) in USA (Intratumoural, Injection)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Prostate-cancer(Late-stage disease, Metastatic disease) in USA (Intratumoural, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top